A Single Arm Phase 2 Multicenter Study Determining the Response to Cabazitaxel in Metastatic Prostate Cancer (mCRPC) Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)
Latest Information Update: 03 Aug 2023
Price :
$35 *
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CABA-V7
- 06 Oct 2022 Results published in the European Journal of Cancer
- 19 Aug 2021 Planned End Date changed from 1 Oct 2020 to 19 Aug 2022.
- 19 Aug 2021 Planned primary completion date changed from 1 Sep 2019 to 1 Jan 2022.